Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8WVQ1
UPID:
CANT1_HUMAN
Alternative names:
Apyrase homolog; Putative MAPK-activating protein PM09; Putative NF-kappa-B-activating protein 107
Alternative UPACC:
Q8WVQ1; B4DJ54; Q7Z2J7; Q8NG05; Q8NHP0; Q9BSD5
Background:
Soluble calcium-activated nucleotidase 1, also known as Apyrase homolog, Putative MAPK-activating protein PM09, and Putative NF-kappa-B-activating protein 107, exhibits a calcium-dependent nucleotidase activity with a preference for UDP. This enzyme plays a crucial role in proteoglycan synthesis, impacting various biological processes.
Therapeutic significance:
Linked to diseases such as Desbuquois dysplasia 1 and Epiphyseal dysplasia, multiple, 7, Soluble calcium-activated nucleotidase 1's involvement in these conditions underscores its potential as a target for therapeutic intervention. Understanding the role of Soluble calcium-activated nucleotidase 1 could open doors to potential therapeutic strategies.